BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in Heart Failure with Preserved Ejection Fraction
![BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in Heart Failure with Preserved Ejection Fraction](/media/media/img/siteimg/14.png)
Recruiting
18-99 years
All
Phase
1
50 participants needed
1 Location
Brief description of study
The
purpose of the study is to compare how amlodipine versus metoprolol effect
blood pressure in people with HFpEF.
While
hypertension is the most common risk factor for HFpEF, there is little evidence
on the potential role of common antihypertensive medications, specifically
calcium channel blockers (like amlodipine) and β-blockers (like metoprolol), in
the management of hypertension in HFpEF. The goal of this study is to better
understand the mechanistic effects of these two antihypertensive medications in
people with HFpEF so that we can potentially use these medications in the
future to improve long-term blood pressure management, heart function, and symptom
management.
Detailed description of study
The
research study is being conducted to evaluate if different types of commonly
used blood pressure medications (amlodipine and metoprolol) have different
effects on blood pressure, exercise capacity, quality of life, and heart
function in individuals with heart failure with preserved ejection fraction
(HFpEF).
If
you agree to join the study, you will be asked to complete the following
research procedures:
·
Three to four study visits, including physical exams, blood draws,
questionnaires, echocardiograms, arterial tonometry, and exercise testing
·
Taking the study medications at home for approximately four weeks
each
·
Self blood pressure monitoring at home
Your
participation will last for approximately three months.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
heart failure,hypertension,HFpEF
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 833517
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting